IN2014CH00062A - - Google Patents
Info
- Publication number
- IN2014CH00062A IN2014CH00062A IN62CH2014A IN2014CH00062A IN 2014CH00062 A IN2014CH00062 A IN 2014CH00062A IN 62CH2014 A IN62CH2014 A IN 62CH2014A IN 2014CH00062 A IN2014CH00062 A IN 2014CH00062A
- Authority
- IN
- India
- Prior art keywords
- compositions
- optionally
- carbapenem
- stabilizer
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN62CH2014 IN2014CH00062A (ja) | 2014-01-07 | 2014-12-31 | |
PCT/US2014/072996 WO2015105720A1 (en) | 2014-01-07 | 2014-12-31 | Stabilised carbapenem compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN62CH2014 IN2014CH00062A (ja) | 2014-01-07 | 2014-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CH00062A true IN2014CH00062A (ja) | 2015-07-10 |
Family
ID=53524262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN62CH2014 IN2014CH00062A (ja) | 2014-01-07 | 2014-12-31 |
Country Status (2)
Country | Link |
---|---|
IN (1) | IN2014CH00062A (ja) |
WO (1) | WO2015105720A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114224854A (zh) * | 2022-02-14 | 2022-03-25 | 成都晶富医药科技有限公司 | 注射用厄他培南及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA62920C2 (en) * | 1996-05-28 | 2004-01-15 | Merck & Co Inc | Carbapeneme antibiotic, a composition and a method for the preparation |
CN102026621A (zh) * | 2008-05-15 | 2011-04-20 | 巴克斯特国际公司 | 稳定的药物制剂 |
CN102558182B (zh) * | 2010-12-31 | 2015-02-11 | 石药集团中奇制药技术(石家庄)有限公司 | 一种厄他培南钠晶型及其制备方法 |
-
2014
- 2014-12-31 IN IN62CH2014 patent/IN2014CH00062A/en unknown
- 2014-12-31 WO PCT/US2014/072996 patent/WO2015105720A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2015105720A1 (en) | 2015-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501512A1 (en) | Treatment for resistant acne | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
MX2018001075A (es) | Agentes terapeuticos y profilacticos antibacterianos. | |
PH12015501648B1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
MX2017001279A (es) | Usos y composiciones de la flagelina. | |
PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
MX2017009720A (es) | Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas. | |
MX2015010191A (es) | Metodos para tratar infecciones microbianas, incluyendo mastitis. | |
MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
MX2015008486A (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
AU2016356504A8 (en) | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential | |
PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
MX2017006138A (es) | Composiciones farmaceuticas de accion prolongada para hepatitis c. | |
IN2014CH00062A (ja) | ||
PH12018500339A1 (en) | Lysobactin for use in the treatment of bovine mastitis |